Brazilian Health Regulatory Agency ANVISA has granted marketing approval to Zylox-Tonbridge Medical Technology’s ZENFlow Tiger LD PTA Dilatation Catheter (ZENFlow Tiger).

With this approval, the company intends to launch the product in the South American market.

ZENFlow Tiger features a tapered tip and short shoulder that enables easier access through complex lesions thereby facilitating in protecting normal blood vessels.

Its coaxial catheter shaft design also allows for rapid inflation and deflation. It is available in various sizes for use in different clinical needs.

The low-temperature molding technology ensures non-compliance while the braided delivery shaft provides pushability and kink resistance.

The company also anticipates using ZENFlow Tiger in treating Budd-Chiari syndrome, iliac vein compression syndrome, and other peripheral vascular occlusions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also expects better treatment efficacy of the product, when properly used along with mechanical thrombectomy devices and peripheral stents.

This April, Zylox-Tonbridge formed a strategic alliance with Guangdong Hicicare Science to facilitate the commercialisation of vascular guidewire products, under a co-branded label in China.

The partnership’s aim is to bring new neuro and peripheral-vascular interventional devices to Chinese physicians and patients.

The company generated a revenue of 6.23m yuan ($0.85m), representing a YoY increase of 128.7% during the first half of this year.